ReviewCurrent diabetes reports2019
Diabetes and Cardiovascular Disease: an Update.
Review in Current diabetes reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- A Systematic Review and Meta-Analytic Assessment of Unpredictability and Disordered Eating.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- A meta-analysis on the prevalence, associated factors and diagnostic methods of mental stress induced myocardial ischemia.Journal of translational medicine · 2020Pooled it
- Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis.Diabetes & vascular disease researchPooled it
- Sequence of episodic memory-related behavioral and brain-imaging abnormalities in type 2 diabetes.Nutrition & diabetes · 2025Trial
- Evaluation of Short-Term Insulin Pump for Treatment of Patients with Type 2 Diabetes Mellitus Complicated with Lower Extremity Arterial Disease in Endocrinology by Ultrasonography.Computational and mathematical methods in medicine · 2022Trial
- Association of multimorbidity and its patterns with risk of mortality among the elderly in Shenzhen, China.BMC geriatrics · 2026Article
- Lipotoxicity in Diabetic Cardiomyopathy: Molecular Basis and Emerging Therapeutic Targets.International journal of molecular sciences · 2026Review
- Regression from prediabetes to normoglycaemia and the role of cardiometabolic risk factors on the subsequent risk of developing type 2 diabetes.Diabetologia · 2026Article
- Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- Air pollution, temperature, and HbA1c levels among children in Mexico City, Mexico.Ecotoxicology and environmental safety · 2025Article
- Generative artificial intelligence in predictive analysis of diabetes and its complications: a narrative review.Annals of translational medicine · 2025Review
- Cancer beliefs, risk perceptions, and health protective behaviors among people living with diabetes in the United States: Results from the Health Information National Trends Survey.Preventive medicine reports · 2025Article
- Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study.Journal of the American Heart Association · 2025Article
- Efficacy of exercise and electromagnetic field therapy on cardiovascular disease risk in patients with type 2 diabetes mellitus. Randomized controlled trial.American journal of cardiovascular disease · 2025Article
- Article
- Therapeutic potential ofFrontiers in nutrition · 2025Review
- Prognostic value of the neutrophil to lymphocyte ratio for cardiovascular diseases: research progress.American journal of translational research · 2025Review
- Prevalence of diabetes and its associated factors in Cape Verde: an analysis of the 2020 WHO STEPS survey on non-communicable diseases risk factors.BMC endocrine disorders · 2024Article
- Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies.Reviews in cardiovascular medicine · 2024Review
- Effective protective mechanisms of HO-1 in diabetic complications: a narrative review.Cell death discovery · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCardiovascular disease (CVD) is the leading cause of mortality in people with diabetes. Our aim was to review the pathophysiology of CVD in diabetes, review related landmark trials, and discuss the cardiovascular benefit of glucose-lowering agents. We have also discussed the role of controversial anti-platelet therapy. RECENT
findingsRecent studies have shown the impact of glucose-lowering agents on CVD in people with diabetes. Statins are now recommended for all patients with diabetes over the age of 40 regardless of the LDL level given the cardiovascular benefit of these drugs. Current recommendations suggest a blood pressure < 130/80 for individuals with high cardiovascular risk. Cardiovascular risk reduction should be an important part of the management of diabetes. Focusing solely on glycemic control may not be the best therapeutic strategy. Multifactorial risk reduction should be taken into account. Lipid-lowering agents and anti-hypertensives should be a corner stone of treatment of diabetes. With currently available data, glucose-lowering agents with cardiovascular benefit should be started early in the disease process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.